Journal of Hebei Medical University ›› 2023, Vol. 44 ›› Issue (2): 179-183.doi: 10.3969/j.issn.1007-3205.2023.02.011

Previous Articles     Next Articles

Efficacy of 5-aminoketovaleric acid photodynamic therapy in the treatment of VLS and its effect on the expression levels of TGF-β1 and p16

  

  1. Department of Gynaecology, Chengde Maternal and Child Health Hospital, Hebei Province, Chengde 067000, China

  • Online:2023-02-25 Published:2023-02-28

Abstract: Objective To investigate the efficacy of 5-aminoketovaleric acid photodynamic therapy (5-ALA-PDT) in the treatment of vulvar lichen sclerosus (VLS) and its effect on the expression levels of transforming growth factor-β1 (TGF-β1) and p16. 
Methods A total of 146 patients with VLS admitted to the Department of Gynecology, Chengde Maternal and Child Health Hospital in Hebei Province were selected and divided into two groups according to the random number table method: 73 cases in the observation group received 5-ALA-PDT and 73 cases in the control group received Halometasone cream. Clinical efficacy, Cattaneo scores, TGF-β1 mRNA and p16 mRNA expression in VLS tissues and recurrence rates between two groups were compared. 
Results Compared with the control group, the observation group had a higher total effective rate (P<0.05).Compared with the control group after treatment, pruritus, skin elasticity, skin colour, lesion extent score,TGF-β1 mRNA expression in VLS tissue was lower and p16 mRNA expression was higher in the observation group (P<0.05). At 6-month follow-up, the recurrence rate was lower in the observation group than in the control group (P<0.05).No serious adverse reactions were observed in either group.
Conclusion 5-ALA-PDT is effective in the treatment of VLS, which can improve both subjective and objective symptoms, and reduce TGF-β1 mRNA, p16 mRNA expression and recurrence rate in VLS tissues. 


Key words: vulvar lichen sclerosus, 5-aminoketovaleric acid photodynamic therapy, transforming growth factor-β